Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up

Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up

PURPOSEMajor progress has occurred in multiple myeloma (MM) treatment in recent years, but this is not seen in low- and middle-income countries.MATERIALS AND METHODSWe retrospectively assessed the efficacy and safety of cyclophosphamide, thalidomide, and dexamethasone (cyclophosphamide 400 mg/m2 for...

Full description

Bibliographic Details
Main Authors:	Jule Vasquez, Rossana Ruiz, Karina Aliaga, Fernando Valencia, Marco Villena, Shirley Quintana, Tatiana Vidaurre, Luis Casanova
Format:	Article
Language:	English
Published:	American Society of Clinical Oncology 2021-12-01
Series:	JCO Global Oncology
Online Access:	https://ascopubs.org/doi/10.1200/GO.20.00665

Similar Items

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
by: A Santos, et al.
Published: (2021-10-01)

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS
by: EQ Crusoe, et al.
Published: (2021-10-01)

PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
by: E.Q. Crusoé, et al.
Published: (2020-11-01)

IMMUNE PROFILING EVALUATION OF NEWLY DIAGNOSE MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS TREATED WITH DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (DARA-CTD): PRELIMINARY RESULTS
by: A.S. Santos, et al.
Published: (2020-11-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
by: Shutan Li, et al.
Published: (2023-03-01)

Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients
by: Fang Fang, et al.
Published: (2024-01-01)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
by: Enrique M. Ocio, et al.
Published: (2023-02-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
by: Edvan de Queiroz Crusoe, et al.

Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?
by: Afonso Celso Vigorito

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
by: Schütt, P, et al.
Published: (2005)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
by: Kazimierz Groen, et al.
Published: (2023-09-01)

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
by: Ruth Wester, et al.
Published: (2020-08-01)

PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA
by: Rahmathullah Sulaimankutty Nameera, et al.
Published: (2023-08-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

P1067: PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS
by: J.-N. Wang, et al.
Published: (2022-06-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
by: Pieter Sonneveld, et al.
Published: (2020-11-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
by: K. Groen, et al.
Published: (2022-06-01)

PB2011: CHIDAMIDE COMBINED WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (TC2D) AS AN ORAL QUADRUPLET REGIMEN FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: INITIAL RESULTS OF A PHASE IIA, MULTICENTER TRIAL
by: Y. Li, et al.
Published: (2022-06-01)

The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011-12-01)

The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011-12-01)

PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.
by: Celia Martinez, et al.
Published: (2023-08-01)

Restarting Thalidomide-Dexamethasone Regimen in a Post-Abortive Female with Multiple Myeloma: Effective Clinical Response Possible
by: Suhailur Rehman, et al.
Published: (2017-07-01)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
by: Philippe Moreau, et al.
Published: (2021-02-01)

P909: RENAL RESPONSE OF POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT
by: Y. Jian, et al.
Published: (2022-06-01)

P909: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: POMACE PHASE II STUDY
by: Fen Saj, et al.
Published: (2023-08-01)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
by: Ajay K. Nooka, et al.
Published: (2022-04-01)

No influence of the polymorphisms <it>CYP2C19 </it>and <it>CYP2D6 </it>on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
by: Vogel Ulla, et al.
Published: (2010-08-01)

Thalidomide and its analogues in the treatment of Multiple Myeloma
by: Latif Tahir, et al.
Published: (2012-09-01)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
by: Karthik Ramasamy, et al.
Published: (2022-11-01)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
by: X. Jingyu, et al.
Published: (2022-06-01)

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
by: Fen Saj, et al.
Published: (2023-03-01)

Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011-02-01)